Compare iShares MSCI Malaysia ETF (EWM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Nuwellis Inc — how do they compare? iShares MSCI Malaysia ETF trades at $26.39 (market cap $260.46M), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares MSCI Malaysia ETF is far larger — about 118.4× Nuwellis Inc's market cap, and iShares MSCI Malaysia ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 65 Days and Nuwellis Inc for 26 Days on average.
| EWM | NUWE | |
|---|---|---|
Market Cap | $260.46M | $2.20M |
Volume | 90,834 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $146.65 |
52-Week Low | $25.33 | $0.68 |
Typical Hold Time | 65 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM is trading at $26.61, down 1.88% today, with a bearish technical signal from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment. The stock lacks recent news coverage, creating uncertainty around current business developments and financial performance.
The outlook for EWM is cautious due to insufficient fundamental data and bearish technical indicators. Investment opportunities hinge on future earnings clarity, while risks include potential weak financials and negative market sentiment. Investors need updated SEC filings or analyst reports to gauge true valuation and growth prospects.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
